Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Acadia Pharmaceuticals Inc.

< Previous 1 2 3 4 Next >
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference on March 6, 2024
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Announces Additions to Executive Team
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Announces the Passing of Former President Srdjan (Serge) Stankovic
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Delaware District Court Rules in Favor of Acadia on Formulation Patent Construction (Markman) Claims Regarding NUPLAZID® (pimavanserin)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Delaware Federal District Court Rules in Favor of Acadia Pharmaceuticals in NUPLAZID® (pimavanserin) Patent Litigation
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Initiates Pivotal Phase 3 Study of Carbetocin (ACP-101) for the Treatment of Hyperphagia in Prader-Willi Syndrome
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer’s Disease Psychosis
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Announces Change in Research and Development Leadership
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
Acadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating Overview
From Acadia Pharmaceuticals Inc.
Via Business Wire
Tickers ACAD
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.